Sign In
to Vote &
Create Storyboards.
 
Actelion (SIX: ATLN) has announced that following the recent FDA approval and positive CHMP opinion for macitentan (OpsumitĀ®) in pulmonary arterial hypertension (PAH), further positive data on the efficacy of macitentan from the SERAPHIN study were presented at CHEST 2013 in Chicago, USA (26-31 October 2013)...
0
0
0


Storyboard
Print
Share this Article

Recommended

  • {TITLE}
    {PUBLISHER} - {PUBLISHED_DATE}
    {VIEWS}
  • Create Storyboard